Skip to main content

Table 4 Continuous T3 and risk of specific prognostic factors in breast cancer

From: T3 levels in relation to prognostic factors in breast cancer: a population-based prospective cohort study

Tumour group HR (95% CI) HR*(95% CI) HR**(95% CI)
All 1.57 (1.06-2.32) 1.75 (1.18-2.60) 1.89 (1.27-2.82)
Grade I 0.93 (0.40-2.13) 1.00 (0.42-2.39) 1.20 (0.50-2.89)
Grade II 2.45 (1.32-4.55) 2.61 (1.40-4.87) 2.68 (1.42-5.06)
Grade III 1.68 (0.75-3.80) 1.78 (0.80-4.10) 1.86 (0.80-4.36)
Size ≤20 mm 1.53 (0.90-2.60) 1.65 (0.96-2.84) 1.88 (1.09-3.23)
Size >20 mm 1.98 (0.96-4.09) 2.11 (1.01-4.41) 1.96 (0.90-4.26)
Node positive 2.81 (1.39-5.67) 3.13 (1.57-6.23) 3.34 (1.70-6.56)
Node negative 1.18 (0.68-2.05) 1.22 (0.68-2.17) 1.32 (0.73-2.38)
ER positive 1.38 (0.83-2.28) 1.46 (0.87-2.46) 1.60 (0.95-2.71)
ER negative 3.95 (1.97-7.90) 4.15 (2.08-8.30) 4.32 (2.16-8.61)
PGR positive 1.38 (0.82-2.33) 1.48 (0.86-2.53) 1.57 (0.91-2.71)
PGR negative 3.38 (1.74-6.56) 3.53 (1.80-6.89) 3.89 (2.02-7.50)
  1. RR *adjusted for age, RR **adjusted for age and oral contraceptives.
\